ADC Therapeutics SA - Common Shares, par value CHF 0.08 per share (ADCT)

52 filings reported holding ADCT - ADC Therapeutics SA - Common Shares, par value CHF 0.08 per share as of Q1 2024.
ADC Therapeutics SA - Common Shares, par value CHF 0.08 per share (ADCT) has 37 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 34.7M shares of 112M outstanding shares and own 30.99% of the company stock.
Largest 10 shareholders include Redmile Group, LLC (15.3M shares), Prosight Management, LP (7.05M shares), MORGAN STANLEY (2.72M shares), GOLDMAN SACHS GROUP INC (1.54M shares), BANK OF AMERICA CORP /DE/ (1.19M shares), MILLENNIUM MANAGEMENT LLC (1.01M shares), ADAGE CAPITAL PARTNERS GP, L.L.C. (1M shares), CITADEL ADVISORS LLC (952K shares), Vantage Consulting Group Inc (851K shares), and Blue Owl Capital Holdings LP (734K shares).
This table shows the top 37 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.